Modex Therapeutiques S.A., Oxford BioMedica deal

MDXN terminated its 1999 deal with OXB under which MDXN received non-exclusive access to OXB's LentiVector lentiviral vector gene delivery technology to develop a treatment for Type I diabetes (see Bi...